Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25838043 | 1.00 | LMNA (0.50) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25307881 | 0.93 | MAPT (0.50) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25261750 | 0.93 | MAPT (0.50) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25255360 | 0.93 | LMNA (0.48) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25261102 | 0.93 | LMNA (0.48) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL24209569 | 0.93 | MAPT (0.50) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25299762 | 0.93 | MAPT (0.50) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25299266 | 0.93 | MAPT (0.50) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25303320 | 0.91 | MAPT (0.49) | LMNAALDH1A1LPAR1LPAR3MAPT | |
| SCHEMBL25306383 | 0.91 | TLR2 (0.52) | LMNAALDH1A1LPAR1LPAR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| WO-2023135305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295097-A1 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | PRDX5, ANXA5, PRDX1 | LMNA 101/4885ALDH1A1 515/4885LPAR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.